Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. NT-proBNP predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Effects of liraglutide on gallbladder emptying: a randomised, placebo-controlled trial in adults with overweight or obesity

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Antibiotic exposure in early life and childhood overweight and obesity: A systematic review and meta-analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH2

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Gluco-metabolic effects of pharmacotherapy-induced modulation of bile acid physiology

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Effect of the incretin hormones on the endocrine pancreas in end-stage renal disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Linking glycemic dysregulation in diabetes to symptoms, comorbidities, and genetics through EHR data mining

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. N-acyl taurines are endogenous lipid messengers that improve glucose homeostasis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

We investigated the short-term effect of adding liraglutide 1.8 mg once daily to insulin treatment on cardiovascular risk factors in patients with type 1 diabetes. In total, 100 overweight (BMI ≥25 kg/m(2) ) adult patients (age ≥18 years) with type 1 diabetes and HbA1c ≥8% (64 mmol/mol) were randomised to liraglutide 1.8 mg or placebo added to insulin treatment in a 24-week double-blinded, placebo-controlled trial. At baseline and after 24 weeks of treatment, 24-h blood pressure and heart rate, pulse pressure, pulse wave velocity, and carotid intima-media thickness were evaluated. Compared with placebo, liraglutide increased 24-h heart rate by 4.6 beats per min (BPM); p = 0.0015, daytime heart rate by 3.7; p = 0.0240 and nighttime heart rate by 7.5 BPM; p < 0.001 after 24 weeks. Diastolic nocturnal blood pressure increased by 4 mmHg; p = 0.0362 in the liraglutide group compared with placebo. In conclusion, in patients with long-standing type 1 diabetes liraglutide as an add-on to insulin increased heart rate and did not improve other cardiovascular risk factors after 24 weeks of treatment.

Original languageEnglish
JournalDiabetes, Obesity and Metabolism Online
Volume19
Issue number5
Pages (from-to)734-738
Number of pages4
ISSN1463-1326
DOIs
Publication statusPublished - May 2017

ID: 49455504